Ionis Pharmaceuticals (STU:ISI) Total Stockholders Equity : €272.8 Mil (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Total Stockholders Equity?

Ionis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €272.8 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ionis Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €1.87. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ionis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 4.87.

Ionis Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Ionis Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Total Stockholders Equity Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,323.99

610.98

682.99

540.81

354.59

Ionis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															454.46	395.32	295.59	354.59	272.79

Ionis Pharmaceuticals (STU:ISI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ionis Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(272.794	-	0)	/	145.845
	=	1.87

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ionis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.827	+	1287.637)	/	272.794
	=	4.87

Ionis Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (STU:ISI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IONS:USA IONS:Mexico ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (STU:ISI) Headlines

No Headlines